Full-Time

Advanced Practice Provider

Occupational Medicine

Memorial Hermann

Memorial Hermann

10,001+ employees

Integrated health system delivering patient-centered care

No salary listed

Alvin, TX, USA

In Person

Master's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Patient Care
Patient Education

Get referred to Memorial Hermann

See people who can refer or advise you

Requirements
  • A Nurse Practitioner candidate must graduate from a Nurse Practitioner program approved by the State of Texas and hold a master's degree.
  • A Nurse Practitioner candidate must be licensed to practice professional nursing by the State of Texas.
  • A Nurse Practitioner candidate must hold Texas advanced practice registered nurse licensure and be eligible for full prescriptive authority, with possible specialty designations including Certified Registered Nurse Anesthetist, Certified Nurse Midwife, Clinical Nurse Specialist, or Certified Nurse Practitioner.
  • A Nurse Practitioner candidate must hold recognized national certification in the relevant population focus or additional specialty area.
  • A Nurse Practitioner or Physician Assistant candidate must be eligible for Drug Enforcement Administration licensure.
  • A Nurse Practitioner or Physician Assistant candidate must hold Basic Cardiac Life Support or Advanced Cardiac Life Support certification.
  • A Physician Assistant candidate must graduate from a nationally accredited Physician Assistant program.
  • A Physician Assistant candidate must be certified by the National Commission on Certification of Physician Assistants.
  • A Physician Assistant candidate must be licensed by the Texas State Board of Physician Assistant Examiners.
Responsibilities
  • Provide comprehensive patient care through systematic assessment, diagnosis, treatment, management, and follow-up for the approved patient population.
  • Provide health promotion, assess and diagnose patient problems, manage treatment, prescribe pharmacologic and non-pharmacologic interventions, triage patients, and therapeutically manage patient and family needs across the disease process.
  • Practice under the delegation of a supervising physician while maintaining an active prescriptive authority agreement in accordance with regulations and policy.
  • Practice within approved protocols, guidelines, clinical pathways, and evidence-based medicine.
  • Obtain medical histories; perform physical examinations; review, order, and interpret diagnostic tests and radiographic results; formulate and manage treatment plans and outcomes.
  • Provide interventions and perform credentialed procedures within the legal scope and delegated authority, including incision and drainage, pelvic examinations, lesion removal or destruction, suturing, and casting or splinting.
  • Collaborate in the development and evaluation of patient care, update clinical guidelines and protocols, sign orders according to institutional and state board requirements, participate in research and teaching projects, and apply research to practice.
  • Educate patients and families about care resources and participate in process improvement and multidisciplinary clinical outcome improvement activities.
  • Ensure safe care for patients, staff, and visitors and adhere to organizational policies, procedures, standards, budgetary specifications, time-management expectations, supply-management requirements, productivity standards, and quality-of-service standards.
  • Meet mandatory and continuing education and skills-competency requirements, support department-based goals, and serve as a preceptor, mentor, and resource to less experienced staff.
  • Provide compassionate, personalized, safe, and efficient experiences to patients and colleagues in accordance with service standards.
  • Perform other duties as assigned.
Desired Qualifications
  • Two years of clinical experience in the intended practice area is preferred.
  • A master's degree is strongly preferred for the Physician Assistant pathway.

Memorial Hermann Health System is a nonprofit, community-owned health system serving the Greater Houston area with more than 260 care delivery sites. It delivers safe, high-quality, patient-centered care through an integrated network that combines clinical expertise with advanced technology. The system differentiates itself through its community ownership, value-driven culture, and broad network of hospitals, clinics, and specialty services. Its goal is to improve regional health outcomes by providing comprehensive, accessible care and leveraging innovation to personalize treatment.

Company Size

10,001+

Company Stage

Grant

Total Funding

$5M

Headquarters

Houston, Texas

Founded

1907

Get referred to Memorial Hermann

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 Texas funding gave Memorial Hermann $750,000 to add a second stroke unit.
  • Memorial Hermann and Helix launched Genomic Advantage for employees on June 16, 2026.
  • HEAL High School entered its third year, and students have already started paid internships.

What critics are saying

  • February 2026 buyouts signaled margin pressure from ACA subsidy expiration and Medicaid changes.
  • Memorial Hermann cut 350 employees in 2026, showing management expects continued cost resets.
  • Repeated layoffs and buyouts weaken clinical staffing, threatening Memorial Hermann’s trauma and stroke franchises.

What makes Memorial Hermann unique

  • Memorial Hermann built America’s first mobile stroke unit in 2014, now expanding it again.
  • Helix partnership embeds genomic medicine into employee care and workforce risk management.
  • HEAL High School pipelines Houston students into Memorial Hermann nursing and allied-health jobs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Wellness Program

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

14%

1 year growth

14%

2 year growth

14%
The Business Journals
Aug 19th, 2026
Former Houston transplant surgeon's federal case moves toward trial.

Former Houston transplant surgeon's federal case moves toward trial. By Megan Reyna - KHOU 11 Aug 19, 2026 Preview this article 1 min Dr. John Stevenson Bynon, 66, the former surgical director of liver transplantation at Memorial Hermann, is accused of falsifying medical records. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4

AllSci
Jul 8th, 2026
Helix secures AstraZeneca partnership to power drug discovery with US genomic data.

Helix secures AstraZeneca partnership to power drug discovery with US genomic data. July 8, 2026 AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The deal gives AstraZeneca (Nasdaq: AZN) access to Helix's continuously growing, deeply phenotyped cohorts spanning cardiometabolic, respiratory, and autoimmune disease areas. The agreement is AstraZeneca's latest move in a systematic multi-source genomics strategy and arrives as Helix establishes itself as a recurring platform partner to top-tier pharma. Financial terms were not disclosed. GenoSphere cohorts combine Exome+ genomic sequencing with longitudinal electronic health record data averaging 13 years of follow-up per patient, drawn from the Helix Research Network - described by the company as the largest precision health network in North America. The datasets are de-identified and fully consented, with the option to launch targeted follow-on studies. The platform is designed to support target identification, disease biology research, and patient stratification across the drug development lifecycle, functioning as a discovery infrastructure layer rather than a single-indication tool. Helix recently launched its Genomic Advantage program with Nebraska Medicine and Memorial Hermann Health System, adding new health system partners that feed the underlying research network. For AstraZeneca, the Helix deal adds a commercially managed, US-based, exome-sequenced cohort to a genomics portfolio that already includes co-funded access to the UK Biobank whole-genome sequencing dataset and membership in the Alliance for Genomic Discovery - a consortium that includes AbbVie, Amgen, GSK, Merck, and Novo Nordisk, among others. AstraZeneca's Centre for Genomics Research has publicly stated a goal of analyzing 2 million genomes by 2026. The Helix agreement adds a North American commercial data layer to AstraZeneca's existing European biobank partnerships. Helix previously signed a multi-year collaboration with GSK, announced in January 2026 using an identical structural template, with AstraZeneca now the third major pharma to sign onto the same GenoSphere platform following Helix's March 2026 agreement with Alnylam Pharmaceuticals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
Jun 23rd, 2026
Cadence Raises $100M Series C Led by Spark Capital to Automate Chronic Care

Cadence, the clinical AI company managing chronic care for older adults, announced a $100 million Series C, amid adoption of its AI-powered care model across...

PR Newswire
Jun 16th, 2026
Two US health systems launch Helix Genomic Advantage to cut costs through precision medicine

Nebraska Medicine and Memorial Hermann Health System have launched Helix Genomic Advantage, integrating clinical-grade genomic insights into care delivery for their workforces. The programme follows a similar launch with St. Luke's University Health Network. Both health systems are Helix Research Network partners operating large-scale community genomics studies. The Genomic Advantage model aims to implement precision medicine for targeted populations whilst reducing costs, addressing the high expense that has historically prevented scaling diagnostic genomics. "The high cost of diagnostic genomics has served as a significant barrier, preventing health systems from scaling these insights for patient populations," said James Lu, Helix CEO and co-founder. The programme aligns incentives to drive expanded access and total cost of care reduction across risk-based populations.

McIlroy Insurance Group
Jun 16th, 2026
Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know

Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know